The broader initial public offering market is currently playing a waiting game, with investors anticipating a blockbuster filing from Anthropic as the weekly calendar remains largely empty of large deals. Meanwhile, AI-focused cloud firm Nscale is encountering pushback from investors regarding its targeted valuation.
Despite the cautious market mood, the biotech sector defied expectations last week with strong performances. Cancer biotech Iambic Therapeutics (IAM) surged nearly 49 percent from its $16 IPO price to close the week at $23.81. At the same time, City Therapeutics (CTY) made a strong debut on the NASDAQ, ending its first trading session up 24.44 percent at $22.40.
As the market awaits further major developments, only two small deals are slated to be priced. Investors continue to monitor valuations closely, while analysts remind market participants to verify all proposed stock symbols before trading.
